New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety
Retrieved on:
Mercredi, novembre 8, 2023
BOSTON, Nov. 8, 2023 /PRNewswire/ -- ArisGlobal, creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology's ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications.
Key Points:
- A foundational and comparative study of ArisGlobal's LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives).
- She commented: "Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug's addressable market.
- "But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality.
- ArisGlobal's CEO, Mike Gordon, commented, "Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring."